AstraZeneca, Ionis drug fails big heart disease study in major setback
Source: BioPharma Dive - Latest News
Eplontersen’s failure in transthyretin-mediated amyloidosis cardiomyopathy caught Wall Street analysts by surprise and boosted the outlook of rival drugs from Alnylam and BridgeBio Pharma.